No phaseStatus unknownHealthspan endpoint
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Academic or other)
- Enrollment
- 87 planned
- Conditions
- Type 2 Diabetes Mellitus; Obesity; Cognitive Impairment
- Interventions
- Liraglutid; Dapagliflozin; Acarbose
- Ages
- adults, older adults
- Registry
- NCT03961659
Full record on ClinicalTrials.gov
From the registry
This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with type 2 diabetes mellitus(T2DM) inadequately controlled with metformin monotherapy.
Primary outcomes
- Change of olfactory brain activation by fMRI
History
Study completion
Primary completion
Registered
Started